AstraZeneca PLC (AZN) Financials
Key financial figures for AstraZeneca PLC (Q2 2026).
AstraZeneca posted Q2 2026 revenue of $15.38 billion (+6% reported, +5% CER) and Core EPS of $2.63 (+21% reported, +18% CER), while disclosing that the Phase III CARDIO-TTRansform trial of Wainua in ATTR cardiomyopathy missed its primary endpoint. Q2 2026 Total Revenue reached $15.38 billion, up 6% reported (5% CER), with H1 2026 revenue of $30.67 billion, up 9% reported (6% CER). Q2 2026 Reported EPS was $1.61 (+2% reported, -2% CER); Core EPS was $2.63 (+21% reported, +18% CER). Core operating margin was 34% (+2pp). Oncology remained the largest therapy area at $7.33 billion in Q2 (+16% reported), led by Enhertu (+47% reported to $338 million) and Imfinzi (+27% to $1.85 billion). On the outlook: AstraZeneca reconfirmed FY2026 guidance at constant exchange rates: Total Revenue is expected to increase by a mid-to-high single-digit percentage and Core EPS is expected to increase by a low double-digit percentage, with a Core tax rate of 18-22%. Figures are for Q2 2026, as AstraZeneca PLC reported them.
- Revenue
- $15.4B
- Net Income
- $2.5B
- EPS
- $1.60
- Total Assets
- $115.7B
- Operating Cash Flow
- $2.9B
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $15.4B | $2.5B | $1.59 | 20.57% | $2.1B |
| Q1 FY2026 | $15.3B | $3.1B | $1.97 | 27.77% | $1.8B |
| Q4 FY2025 | $15.5B | $2.3B | $1.48 | 19.21% | $1.4B |
| Q3 FY2025 | $15.2B | $2.5B | $1.62 | 23.59% | $3.4B |
| Q2 FY2025 | $14.5B | $2.5B | $1.57 | 24.27% | $1.5B |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $58.7B | $10.3B | $6.54 | 23.4% | $8.7B |
| FY2024 | $54.1B | $7.0B | $4.50 | 18.5% | $7.3B |
| FY2023 | $45.8B | $6.0B | $3.81 | 17.88% | $6.6B |
Frequently asked questions
What was AstraZeneca PLC's revenue last quarter?
AstraZeneca PLC reported revenue of $15.38 billion for Q2 FY2026, up 6.4% from the same period a year earlier.
Is AstraZeneca PLC profitable?
Yes. AstraZeneca PLC reported net income of $2.51 billion for Q2 FY2026, a net margin of 16.3% on revenue.
How has AstraZeneca PLC's margin trended?
Operating margin was 20.57% in Q2 FY2026, compared with 24.27% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did AstraZeneca PLC generate?
AstraZeneca PLC generated free cash flow of $2.13 billion in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for AstraZeneca PLC on SentiSense, with up to forty quarters and twenty fiscal years of history.